<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002872</url>
  </required_header>
  <id_info>
    <org_study_id>EH 09-156</org_study_id>
    <nct_id>NCT01002872</nct_id>
  </id_info>
  <brief_title>The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease</brief_title>
  <official_title>The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 (FGF23 ) in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthShore University HealthSystem Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NorthShore University HealthSystem Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus
      binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease (CKD).

      Targeting FGF23 measurement in CKD patients may impact both the progression of kidney disease
      and patient mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind randomized placebo controlled pilot study. Subjects with Chronic
      Kidney Disease ( CKD) stages 3-5 who are not undergoing renal replacement therapy and have
      not been started on phosphate binders will be randomized to either lanthanum carbonate 1500
      mg daily or placebo for a 60 day treatment period. Patient doses will be increased up to a
      maximum dose of 3000 mg if the serum phosphate is greater than 5.5 mg/dL.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the effects on Lanthanum Carbonate on c terminal and intact FGF 23 level</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline serum calcium and albumin</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline serum phosphate</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline serum parathyroid hormone</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline 1,25 dihydroxyvitamin D 3</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline 25 hydroxyvitamin D</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline serum alkaline phosphatase</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline serum osteocalcin</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline 24 hour urine, calcium,phosphorus, creatinine</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metabolic Bone Disease</condition>
  <arm_group>
    <arm_group_label>Lanthanum Carbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum Carbonate</intervention_name>
    <description>Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill TID Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus &lt;3.5mg/dL Reduce to 1 pill BID. If Phosphorus &gt;5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is &lt;3.5mg/dL Reduce to 1 pill daily. If phosphorus &gt;5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus &lt;3.5mg/dL stop the drug If phosphorus is &gt;5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner</description>
    <arm_group_label>Lanthanum Carbonate</arm_group_label>
    <other_name>Fosrenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosrenol</intervention_name>
    <description>Initial dose of drug will be 1500mg TID</description>
    <arm_group_label>Lanthanum Carbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Initial dose of placebo will be 1 pill three times a day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-pregnant females ages 18 years of age or older

          -  Estimated GFR between 15-60 ml/min/1.73m

          -  Serum phosphate &gt; 3.5 mg/dL

          -  FGF2 &gt; 100RU/mL

          -  Corrected serum clacium &gt;8.0mg/dL

        Exclusion Criteria:

          -  Current use of a phosphate binder

          -  Corrected serum calcium &lt;8.0mg/dL

          -  Current use of prescription-based vitamin D therapy

          -  Acute kidney injury in last 3 months

          -  Significant GI disorder

          -  History of allergic reaction or sensitivity to lanthanum carbonate

          -  History of non compliance with visits or medications that preclude study compliance in
             the opinion of the investigator

          -  Pregnant or able to become pregnant and unwilling to use a birth control method
             considered reliable by the principal investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart M Sprague, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stubbs JR, Quarles LD. Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease? Nephrol News Issues. 2009 May;23(6):33-4, 36-7. Review.</citation>
    <PMID>19534362</PMID>
  </results_reference>
  <results_reference>
    <citation>Saji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, Hatamura I, Shigematsu T. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol. 2009;111(4):p59-66. doi: 10.1159/000210389. Epub 2009 Apr 1.</citation>
    <PMID>19339809</PMID>
  </results_reference>
  <results_reference>
    <citation>Ibrahim S, Rashed L. Serum fibroblast growth factor-23 levels in chronic haemodialysis patients. Int Urol Nephrol. 2009;41(1):163-9. doi: 10.1007/s11255-008-9466-0. Epub 2008 Oct 7.</citation>
    <PMID>18839328</PMID>
  </results_reference>
  <results_reference>
    <citation>Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS, White KE, Gattone VH 2nd. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int. 2009 Jan;75(2):176-84. doi: 10.1038/ki.2008.456. Epub 2008 Sep 17.</citation>
    <PMID>18800026</PMID>
  </results_reference>
  <results_reference>
    <citation>Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F; MMKD Study Group, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007 Sep;18(9):2600-8. Epub 2007 Jul 26.</citation>
    <PMID>17656479</PMID>
  </results_reference>
  <results_reference>
    <citation>Fukagawa M, Kazama JJ. FGF23: its role in renal bone disease. Pediatr Nephrol. 2006 Dec;21(12):1802-6. Epub 2006 Aug 24. Review.</citation>
    <PMID>16932898</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2009</study_first_submitted>
  <study_first_submitted_qc>October 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2009</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NorthShore University HealthSystem Research Institute</investigator_affiliation>
    <investigator_full_name>Stuart M Sprague</investigator_full_name>
    <investigator_title>Chief, Division of Nephrology and Hypertension Professor of Medicine University of Chicago Medical School</investigator_title>
  </responsible_party>
  <keyword>FGF23</keyword>
  <keyword>CKD</keyword>
  <keyword>Fosrenol</keyword>
  <keyword>Hyperphosphatemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

